Stocks Health care HSCS

NASDAQ · Health care

HeartSciences Inc. (HSCS)

HeartSciences Inc. brought in $4.5K of revenue over the twelve months to July 31, 2026. It posted a net loss of $10.3M. In fiscal 2026 capital spending exceeded operating cash flow by $7.4M. At July 31, 2026 it held $29.9K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 14, 2026.

Watch HSCS in 60 seconds

Follow HSCS

Free, no password. An email when HSCS files with the SEC.

Key facts about HeartSciences Inc.

Net worth

HeartSciences Inc. has a market value (market cap) of $9.1M at the latest share price, and shareholders' equity of -$2M on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2026 revenue was $4.3K (-0.7% year on year), with a net loss of $9.1M. Over the 12 months to July 31, 2026: revenue $4.5K, net loss $10.3M.

Cash flow

In fiscal 2026 operations used $7.4M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on September 14, 2026 and covers the period to July 31, 2026. Open on SEC EDGAR

What HeartSciences Inc. does

HeartSciences Inc. is registered with the SEC under industry code SIC 6199 (Finance Services). Its shares trade on NASDAQ under the ticker HSCS.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where HSCS ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What HeartSciences Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. October 6, 2026
   Additional proxy material DEFA14A
2. October 6, 2026
   Investor disclosure 8-K
3. October 6, 2026
   Additional proxy material DEFA14A
4. October 6, 2026
   Form PRER14A filing PRER14A
5. October 2, 2026
   Additional proxy material DEFA14A
6. October 2, 2026
   Material agreement8-KHeartSciences extended the maturity date of its $500,000 secured loan with Front Range Ventures LLC.
7. September 30, 2026
   Additional proxy material DEFA14A
8. September 25, 2026
   Shelf registration to sell securities S-3
9. September 24, 2026
   Additional proxy material DEFA14A
10. September 21, 2026
    Additional proxy material DEFA14A

Recent insider filings (Forms 3, 4 and 144): 8, the latest on July 9, 2026. Insider transactions on SEC

Insider trades

What the people running HeartSciences Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns HSCS

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 499,382 shares in total, about $1.2M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about HSCS

What does HeartSciences Inc. do?

HeartSciences Inc. is a company in the Health care sector, listed on NASDAQ as HSCS. Its shares trade on NASDAQ under the ticker HSCS.

What is HeartSciences Inc.'s net worth?

HeartSciences Inc. has a market value (market cap) of $9.1M at the latest share price, and shareholders' equity of -$2M on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is HeartSciences Inc. profitable?

No. Over the twelve months to July 31, 2026 it reported a net loss of $10.3M on revenue of $4.5K.

How much revenue does HeartSciences Inc. make?

Over the twelve months to July 31, 2026 HeartSciences Inc. reported revenue of $4.5K.

When did HeartSciences Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on September 14, 2026. It covers the period to July 31, 2026. Its newest filing of any kind is the additional proxy material from October 6, 2026.

Similar companies

Compare HSCS with

Compare HSCS with any company

Follow HSCS

Get an email when HeartSciences Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow HSCS

Free, no password. An email when HSCS files with the SEC.

Where the numbers come from

Financial figures are the values HeartSciences Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.